CytomX Therapeutics (NASDAQ:CTMX) Sees Unusually-High Trading Volume Following Analyst Upgrade

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw unusually-high trading volume on Wednesday after Guggenheim raised their price target on the stock from $10.00 to $15.00. Guggenheim currently has a buy rating on the stock. Approximately 9,058,429 shares changed hands during trading, an increase of 56% from the previous session’s volume of 5,799,974 shares.The stock last traded at $4.9640 and had previously closed at $5.45.

Several other research analysts have also issued reports on the company. HC Wainwright increased their price objective on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday. Cantor Fitzgerald boosted their target price on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $7.00 to $12.00 in a report on Monday. Piper Sandler increased their target price on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Finally, Barclays boosted their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.13.

Key Headlines Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Positive Phase I Varseta‑M (CX‑2051) data drove a surge in investor interest, showing dose‑dependent responses in late‑line colorectal cancer and underpinning recent upgrades and price‑target increases. CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
• Positive Sentiment: Several analysts raised ratings/targets after the clinical update — JPMorgan upgraded CTMX to overweight (higher conviction) and Wedbush raised its price target — providing buy‑side validation that upside remains tied to Varseta‑M progress. CytomX Therapeutics Stock Rating Upgraded by JPMorgan Chase & Co.
• Neutral Sentiment: HC Wainwright maintained a constructive view (Buy) and a high $17 price target while updating its models — the PT signals strong upside potential but relies heavily on successful Varseta‑M development. MarketBeat CTMX Coverage
• Negative Sentiment: CytomX priced an underwritten public offering to raise about $250M at $5.30 per share (and pre‑funded warrants), which dilutes existing shareholders and increases share overhang—a primary driver of the stock pullback. CytomX Announces Pricing of $250M Offering
• Negative Sentiment: Q4 results missed estimates: EPS and revenue came in below expectations, reinforcing near‑term financial pressure and validating analyst EPS downgrades. That miss amplified selling after the clinical‑driven rally. CTMX Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: HC Wainwright materially lowered EPS forecasts across 2026 quarters and cut FY2026 expectations (reflecting higher cash burn/near‑term losses), which can temper analyst confidence until clearer clinical or commercial milestones are reached. MarketBeat CTMX Coverage

Hedge Funds Weigh In On CytomX Therapeutics

A number of large investors have recently modified their holdings of CTMX. Squarepoint Ops LLC grew its stake in shares of CytomX Therapeutics by 4.5% during the fourth quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 2,169 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares in the last quarter. Velan Capital Investment Management LP raised its position in CytomX Therapeutics by 6.7% in the 3rd quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 5,000 shares during the last quarter. Farther Finance Advisors LLC acquired a new position in CytomX Therapeutics during the 3rd quarter worth $25,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in CytomX Therapeutics during the 4th quarter worth $35,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Performance

The stock has a market capitalization of $834.78 million, a P/E ratio of -123.63 and a beta of 2.44. The stock has a 50-day simple moving average of $5.26 and a 200 day simple moving average of $4.09.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 20.65%. The firm had revenue of $0.66 million during the quarter, compared to analyst estimates of $7.33 million. Equities analysts predict that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.